#### Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

#### ENDO PHARMACEUTICALS HOLDINGS INC

Form 4

November 03, 2005

FΟ	RM	4
----	----	---

Check this box

if no longer

Section 16.

subject to

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** Number:

3235-0287

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires: 2005

**OMB APPROVAL** 

Estimated average

burden hours per

**SECURITIES** 

response... 0.5

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **ENDO PHARMA LLC** 

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

below)

Symbol

(Middle)

**ENDO PHARMACEUTICALS** HOLDINGS INC [ENDP]

(Check all applicable)

(Last) (First) 3. Date of Earliest Transaction

Director Officer (give title \_X\_\_ 10% Owner \_ Other (specify

320 PARK AVENUE

(Street)

(Month/Day/Year) 11/02/2005

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line) \_X\_ Form filed by One Reporting Person

Form filed by More than One Reporting

Filed(Month/Day/Year)

Person

NEW YORK, NY 10022

per share

(City)	(State)	Zip) Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)  (A) or		Beneficially (D) or Owned Indirect (I) Following (Instr. 4) Reported Transaction(s)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
G			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock, par value \$.01 per share	11/02/2005		X	152	D	\$ 2.42	21,522,048	D	
Common Stock, par value \$.01 per share	11/02/2005		X	2,400	D	\$ 2.42	21,519,648	D	
Common Stock, par value \$.01	11/02/2005		X	5,133	D	\$ 2.42	21,514,515	D	

### Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Common Stock, par value \$.01 per share	11/02/2005	X	18,182	D	\$ 2.42	21,496,333	D
Common Stock, par value \$.01 per share	11/02/2005	X	7,098	D	\$ 2.42	21,489,235	D
Common Stock, par value \$.01 per share	11/02/2005	X	10,850	D	\$ 3	21,478,385	D
Common Stock, par value \$.01 per share	11/02/2005	X	1,084	D	\$ 3	21,477,301	D
Common Stock, par value \$.01 per share	11/02/2005	X	4,159	D	\$ 3	21,473,142	D
Common Stock, par value \$.01 per share	11/02/2005	X	1,160	D	\$ 3.42	21,471,982	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	orDeriva Securi Acqui	red (A) posed of 3, 4,	Expiration Date Undo (Month/Day/Year) (Inst		Underlying S	Title and Amount of the and Amount of the and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share	
Call Option (obligation to sell)	\$ 2.42	11/02/2005		X		152	10/13/2005	08/26/2007	Common Stock	152	

#### Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Call Option (obligation to sell)	\$ 2.42	11/02/2005	X	2,400	10/13/2005	08/26/2007	Common Stock	2,400
Call Option (obligation to sell)	\$ 2.42	11/02/2005	X	5,133	10/13/2005	08/26/2007	Common Stock	5,133
Call Option (obligation to sell)	\$ 2.42	11/02/2005	X	18,182	10/13/2005	08/26/2007	Common Stock	18,182
Call Option (obligation to sell)	\$ 2.42	11/02/2005	X	7,098	10/13/2005	08/26/2007	Common Stock	7,098
Call Option (obligation to sell)	\$ 3	11/02/2005	X	10,850	10/13/2005	08/26/2007	Common Stock	10,850
Call Option (obligation to sell)	\$ 3	11/02/2005	X	1,084	10/13/2005	08/26/2007	Common Stock	1,084
Call Option (obligation to sell)	\$ 3	11/02/2005	X	4,159	10/13/2005	08/26/2007	Common Stock	4,159
Call Option (obligation to sell)	\$ 3.42	11/02/2005	X	1,160	10/13/2005	08/26/2007	Common Stock	1,160

### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
• 0	Director	10% Owner	Officer	Other			
ENDO PHARMA LLC 320 PARK AVENUE		X					
NEW YORK, NY 10022							

## **Signatures**

/s/ Jeffrey R. Black Chief Financial Officer 11/03/2005

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3